Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Shopify Inc. (SHOP) vs Viatris Inc (VTRS) Price & Performance

Shopify Inc.Trade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Shopify Inc. vs Viatris Inc — how do they compare? Shopify Inc. trades at $170.85 (market cap $211.73B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Shopify Inc. is far larger — about 10.6× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while Shopify Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Shopify Inc. for 78 Days and Viatris Inc for 57 Days on average.

SHOPVTRS
Market Cap
$211.73B$20.03B
Volume
7,146,65114,109,977
Sector
TechnologyHealth
52-Week High
$179.01$18.27
52-Week Low
$95.40$9.74
Typical Hold Time
78 Days57 Days
Enterprise Value
$206.96B$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Shopify Inc.

Shopify (SHOP) trades at $164.54, down 0.84% on the day, with strong technical momentum showing bullish moving average signals despite overbought RSI readings. The company demonstrates robust revenue growth, with 2025 revenue reaching $11.56 billion and net income of $1.23 billion, though valuation metrics remain elevated with a P/E of 111. Recent developments include the launch of Canvas AI store-building tools and expanding payment services.

Shopify maintains strong growth trajectory with accelerating merchant solutions revenue and expanding AI capabilities. However, premium valuation multiples and competitive pressures from Amazon pose risks. Analyst consensus remains bullish with 67% buy ratings and $168.63 price target, suggesting modest upside potential from current levels.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SHOP
100% Buy0% Sell
Avg holding period · 78 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Shopify Inc.

Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.

Read more on SHOP →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →